Possível uso da Psilocibina no tratamento psiquiátrico, incluindo sequelas da COVID-19
DOI:
https://doi.org/10.33448/rsd-v10i11.19259Palavras-chave:
Psilocibina; Psiquiatria; Depressão; Ansiedade; Cuidados paliativos; Alucinógenos.Resumo
Este trabalho discute acerca da ação da psilocibina no organismo humano e seu potencial terapêutico enquanto tratamento principal ou adjuvante para certos distúrbios psiquiátricos, mais especificamente a depressão e a ansiedade, como aquelas encontradas em pacientes que estão em cuidados paliativos e enfrentando o processo de fim de vida, mas também em pacientes nos quais o tratamento convencional não demonstrou eficácia. Estudos recentes também indicam a possibilidade da utilização da psilocibina no tratamento de sequelas psiquiátricas a longo prazo decorrentes da COVID. A literatura disponível indica que a psilocibina promove aumento da qualidade de vida, alterações na percepção do self, percepção de integralidade com o meio e experiências espirituais, o que se mostra especialmente importante nos grupos de pacientes supracitados. Além disso, demonstra pouco ou nenhum efeito colateral. Este trabalho realiza uma revisão para ratificar a hipótese do uso terapêutico da psilocibina na depressão e na ansiedade em populações que mais podem se beneficiar da terapia psicodélica.
Referências
Aversi-Ferreira et al. (2013). Confrontation between ethnopharmacology and scientific results of the herbal medicaments from Brazil to be applied in primary health care. Journal of Medicinal Plants Research, 7(14), 845-856.
Barnby, J. M. & Mehta, M. A. (2018). Psilocybin and mental health-don't lose control. Front. Psychiatry, 3. DOI: https://doi.org/10.3389/fpsyt.2018.00293.
Bershad, A. K. et al. (2019). Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biological Psychiatry, 86(10), 792-800. DOI: https://doi.org/10.1016/j.biopsych.2019.05.019.
Bloch, S. et al. (2007). Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med, 1(2). DOI: https://doi.org/10.1186/1751-0759-1-2.
Bonn-Miller, M. O. et al. (2007). Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. J Anxiety Disord, 21(5), 730-41. DOI: https://doi.org/10.1016/j.janxdis.2006.09.014.
Byock, I. (2018). Taking Psychedelics Seriously. Journal of Palliative medicine, 21(4). DOI: https://doi.org/10.1089/jpm.2017.0684.
Carhart-Harris, R. L., Bolstridge, M., Day & C. M. J. et al (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399-408. DOI: https://doi.org/10.1007/s00213-017-4771-x.
Carhart-Harris, R. L., Roseman, L. & Bolstridge, M. et al (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep, 7, 13187. DOI: https://doi.org/10.1038/s41598-017-13282-7.
Carhart-Harris, R. L. et al (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 7, 619-627. DOI: https://doi.org/10.1016/S2215-0366(16)30065-7.
Chang, V. et al (2007). Pain and palliative medicine. Journal of rehabilitation research and development, 44(2), 279-94. DOI: https://doi.org/10.1682/JRRD.2006.06.0067.
Chochinov, H. M. et al. (2009). The landscape of distress in the terminally ill. J Pain Symptom Manage, 38(5), 641-9. DOI: https://doi.org/10.1016/j.jpainsymman.2009.04.021.
Chochinov, H. M. et al. (2008). The patient dignity inventory: a novel way of measuring dignity-related distress in palliative care. J Pain Symptom Manage, 36(6), 559-71. DOI: https://doi.org/ 10.1016/j.jpainsymman.2007.12.018.
Costa et al (2018). The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders. Evidence-Based Complementary and Alternative Medicine. DOI: https://doi.org/10.1155/2018/7686913.
Cowen, P. (2016). Altered states: psilocybin for treatment-resistant depression. Lancet Psychiatry, 3(7), 592-3. DOI: https://doi.org/10.1016/S2215-0366(16)30087-6.
Dos Santos, R. G. et al (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 6(3), 193-213. doi: https://doi.org/10.1177/2045125316638008.
Dos Santos, R. G. et al (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety and substance use disorders: a systematic review of systematic reviews. Expert Review of Clinical Pharmacology, 11(9), 889-902. DOI: https://doi.org/10.1080/17512433.2018.1511424.
Dos Santos, R. G. & Hallak, J. E. C. (2019). Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev, 108, 423-434. DOI: https://doi.org/10.1016/j.neubiorev.2019.12.001.
Erritzoe, D. et al. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatric Scand, 138(5), 368-378. DOI: https://doi.org/10.1111/acps.12904.
Erritzoe, D. et al. (2019). Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenges. Springer Nature – Neuropsychopharmacology, 45(5), 804-810. DOI: 10.1038/s41386-019-0567-5
Gandy, S. (2017). Dying to live: The power of transcendence in the treatment of existential anxiety. Journal of Interdisciplinary Consciousness Studies, 1(2), 25-36. Retrieved from http://www.tjics.org/index.php/TJICS/article/view/14.
Griffiths, R. R.; Richards, W. A. & Mccann, U. et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283. DOI: https://doi.org/10.1007/s00213-006-0457-5.
Griffiths, R. R. et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. DOI: https://doi.org/10.1177/0269881116675513.
Gripp, S. et. al. (2007). Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol, 25(22), 3313-3320. DOI: https://doi.org/10.1200/JCO.2006.10.5411.
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99-120. DOI: https://doi.org/10.1016/j.bbr.2014.07.016.
Hebert, R. et al (2009). Preparing Family Caregivers for Death and Bereavement. Insights from Caregivers of Terminally III Patients. Journal Of Pain And Symptom Management, 37, 3-12. DOI: https://doi.org/10.1016/j.jpainsymman.2007.12.010.
Kelly, J. R. et al (2020). Psychedelic science in post-COVID-19 psychiatry. Irish Journal Of Psychological Medicine, 1–6. DOI: https://doi.org/10.1017/ipm.2020.94.
Kolva, E. et al. (2011). Anxiety in terminally ill cancer patients. J Pain Symptom Manage, 42(5), 691-701. DOI: https://doi.org/10.1016/j.jpainsymman.2011.01.013.
Kraehenmann, R. et al. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological Psychiatry, 78, 572-581. DOI: https://doi.org/10.1016/j.biopsych.2014.04.010.
Kraehenmann, R. et al. (2016). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clinical, 11, 53-60. DOI: https://doi.org/10.1016/j.nicl.2015.08.009.
Lim, C. H.; Kangas, B. & Bergman, J. (2018). The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients. Journal of Young Investigators. DOI: https://doi.org/10.22186/jyi.35.2.45-49.
Ly, C. et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep, 23, 3170-82. DOI: https://doi.org/10.1016/j.celrep.2018.05.022.
McCorvy, J. D; Olsen, R. H. J. & Roth, B. L. (2016). Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of Psychopharmacology, 30(12), 1209-1210. DOI: https://doi.org DOI: http://dx.doi.org/10.1177/0269881116675771.
Mithoefer, M. C.; Grob, C. S & Brewerton, T. D. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry, 3(5):481-8. DOI: http://dx.doi.org/10.1016/ S2215-0366(15)00576-3.
Nutt, D. (2016). Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology, 30(12), 1163-1164. DOI: https://doi.org/10.1177/0269881116675754.
Passie, T. et al. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357-364. DOI: https://doi.org/10.1080/1355621021000005937.
Phelps A.C. et al. (2009). Association between religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. Jama, 301(11), 1140-7. DOI: doi: https://doi.org/10.1001/jama.2009.341.
Preller, K. H. et al. (2017). The fabric of meaning and subjective effects in LSD- induced states depend on serotonin 2A receptor activation. Curr Biol, 27, 451–7. DOI: https://doi.org/ 10.1016/j.cub.2016.12.030.
Preller, K. H. et al. (2020). Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biological Psychiatry, 88(2), 197-207. DOI:https://doi.org/10.1016/j.biopsych.2019.12.027.
Roseman, L.; Nutt, D. J. & Carhart-harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol, 17. DOI: https://doi.org/10.3389/fphar.2017.00974.
Roseman et al. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 142, 263-269. DOI: https://doi.org/10.1016/j.neuropharm.2017.12.041.
Ross, S. (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry, 30(4), 317-330.DOI: https://doi.org/10.1080/09540261.2018.1482261.
Ross S, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol, 30(12), 1165-1180. DOI: https://doi.org/10.1177/0269881116675512.
Rubinstein, E. et al. (2015). A call to action: the global response to dementia through policy innovation. Dementia. 37p. Retrieved from https://www.wish.org.qa/wp-content/uploads/2018/01/WISH_Dementia_Forum_Report_08.01.15_WEB.pdf.
Rucker, J. J. H.; Iliff, J. & Nutt; D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142:200-218. DOI: https://doi.org/ 10.1016/j.neuropharm.2017.12.040.
Salih, L. H; Kaushik, A. (2013). Mini Review on psychedelic drugs: illumination on the hidden aspects of mind. American Journal Of Phytomedicine And Clinical Therapeutics. 1(5), 432-444. Retrieved from https://www.imedpub.com/articles/mini-review-on-psychedelic-drugsillumination-on-the-hidden-aspects-of-mind.pdf.
Schmid, Y; Liechti M. E. (2018). Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 235, 535-45. DOI: https://doi.org/10.1007/s00213-017-4733-3.
Singewald, N. et al. (2015). Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology & Therapeutics, 149, 150-190. DOI: https://doi.org/10.1016/j.pharmthera.2014.12.004.
Sorger, B. et al. (2007). Decision-making capacity in elderly, terminally ill patients with cancer. Behavioral Sciences & The Law, 25, 393-404. DOI: https://doi.org/10.1002/bsl.764.
Tancer M. & Johanson C. E. (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend, 72(1), 33-44. DOI:http://doi.org/10.1016/s0376-8716(03)00172-8.
Tylš, F.; Páleníček, T. & Horáček, J. (2014). Psilocybin – Summary of knowledge and new perspectives. European Neuropsychopharmacology, 24, 342-356. DOI: https://doi.org/10.1016/j.euroneuro.2013.12.006.
Valentiner D. P., Mounts N. S. & Deacon B. J. (2004). Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. J Anxiety Disord, 18(5), 573-85. Retrieved from http://bases.bireme.br/cgibin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=goo-gle&base=ADOLEC&lang=p&nextAction=lnk&exprSearch=15275940&indexSearch=ID.
Watts, R. et al. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 57(5), 1-45. DOI: https://doi.org/10.1177/0022167817709585.
Young K. S. et al. (2017). Treatment for social anxiety disorder alters functional connectivity in emotion regulation neural circuitry. Psychiatry Res Neuroimaging, 30(261), 44-51. DOI: https://doi.org/10.1016/j.pscychresns.2017.01.005.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Myla Chistie Araujo Custodio Bonifácio; Pietra Bruna Batrbosa Bento; Kaynara Trevisan; Renata Cristina Pereira; Micheli Patricia de Fátima Magri; Tales Alexandre Aversi-Ferreira
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
